Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellnovo Group

www.cellnovo.com

Latest From Cellnovo Group

Is Dexcom Piecing Together An Artificial Pancreas Puzzle With TypeZero?

The leader in continuous glucose monitoring, Dexcom has acquired TypeZero Technologies, a specialist in developing algorithms for artificial pancreas systems. Does Dexcom have its sights on expanding beyond glucose monitoring and into insulin delivery, and building an artificial pancreas of its own?

Diabetic Care Commercial

Market Intel: Insulin Pumps Dominate $7bn-Plus Global Infusion Devices Market

The global infusion drug delivery market continues to be driven by the rising prevalence of chronic disease and associated obesity, coupled with a growing aging population. Technological advancements such as less invasive pumps, needlestick prevention features and miniaturization have also supported the growing demand, but obstacles such as safety and security issues remain. According to a new report by Meddevicetracker, the global market for infusion pumps and disposables will reach $9.9bn by 2022, a CAGR of 6.4% from 2017. This article takes an in-depth look at the overall infusion pumps market, and dives deeper into the three fastest-growing segments – insulin, enteral and disposable pumps – highlighting the key players and competitive landscape.

Metabolic Market Intelligence

Boost For European Biotech As €345m Fund Opens

Edmond De Rothschild Investment Partners unveils the largest life science and medical device venture fund to be raised in Europe. Olivier Litzka tells Scrip that the continent can now boast a public market machinery that contributes to potentially lucrative exits for investors.

Financing StartUps and SMEs

Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market

The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.

Diabetic Care Metabolic
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Glucose Testing
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Cellnovo Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Cellnovo Group
  • Senior Management
  • Sophie Baratte, CEO
    Thierry Moulin, CFO
    Julian Shapley, CSO
  • Contact Info
  • Cellnovo Group
    Phone: (44) (0) 1 78 42 40 2
    13 rue de Londre
    Paris, 75009
    France
UsernamePublicRestriction

Register